molecular model for dual strategy


Neurolixis is building a drug discovery and development pipeline:

Development of early-stage clinical assets:

Neurolixis is developing clinical-stage drugs targeted at serious CNS diseases with unmet medical needs and sizeable market opportunity.

NLX-112, is a Phase II-ready drug intended for the treatment of L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for the treatment of breathing difficulties in Rett's syndrome, a genetically-encoded orphan disorder.


Synthesis and development of Novel Chemical Entities (NCEs):

Neurolixis' is exploring validated, but underexploited, pharmacological targets for NCEs, including serotonin and glutamate receptors. New mechanisms of action will be favored, with a focus on "biased agonism".


All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.